statistiche ricercatore

BARTALENA, LUIGI

Distribuzione geografica

Continente	#
NA - Nord America	27.564
EU - Europa	14.494
AS - Asia	9.412
SA - Sud America	963
Continente sconosciuto - Info sul continente non disponibili	293
AF - Africa	211
OC - Oceania	24
AN - Antartide	1
Totale	52.962

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	27.287
IT - Italia	6.551
SG - Singapore	2.793
UA - Ucraina	2.451
CN - Cina	2.016
TR - Turchia	1.438
VN - Vietnam	1.374
DE - Germania	1.015
HK - Hong Kong	997
SE - Svezia	991
BR - Brasile	773
FI - Finlandia	737
IE - Irlanda	700
GB - Regno Unito	654
FR - Francia	493
RU - Federazione Russa	425
BD - Bangladesh	210
IN - India	174
CA - Canada	135
JP - Giappone	111
NG - Nigeria	101
MX - Messico	90
NL - Olanda	66
AR - Argentina	62
PL - Polonia	56
ES - Italia	51
AT - Austria	47
EU - Europa	41
IQ - Iraq	40
BE - Belgio	38
CZ - Repubblica Ceca	38
ZA - Sudafrica	33
CL - Cile	30
ID - Indonesia	30
LT - Lituania	29
PK - Pakistan	29
EC - Ecuador	27
CH - Svizzera	23
IL - Israele	23
MY - Malesia	22
UZ - Uzbekistan	21
CO - Colombia	20
PH - Filippine	16
RO - Romania	16
AE - Emirati Arabi Uniti	15
SA - Arabia Saudita	15
VE - Venezuela	15
KE - Kenya	14
MD - Moldavia	14
EG - Egitto	13
NZ - Nuova Zelanda	13
MA - Marocco	12
NP - Nepal	12
PY - Paraguay	12
AU - Australia	10
HU - Ungheria	10
BG - Bulgaria	9
HN - Honduras	9
PE - Perù	9
TH - Thailandia	9
AZ - Azerbaigian	8
BY - Bielorussia	8
DZ - Algeria	8
TN - Tunisia	8
BO - Bolivia	7
CR - Costa Rica	7
DK - Danimarca	7
KR - Corea	7
MT - Malta	7
RS - Serbia	7
HR - Croazia	6
NO - Norvegia	6
PT - Portogallo	6
TT - Trinidad e Tobago	6
UY - Uruguay	6
BA - Bosnia-Erzegovina	5
DO - Repubblica Dominicana	5
GR - Grecia	5
IR - Iran	5
JM - Giamaica	5
LU - Lussemburgo	5
OM - Oman	5
CI - Costa d'Avorio	4
EE - Estonia	4
GT - Guatemala	4
JO - Giordania	4
KG - Kirghizistan	4
PA - Panama	4
SK - Slovacchia (Repubblica Slovacca)	4
SN - Senegal	4
AL - Albania	3
AM - Armenia	3
BN - Brunei Darussalam	3
KW - Kuwait	3
LB - Libano	3
LK - Sri Lanka	3
MM - Myanmar	3
SI - Slovenia	3
TZ - Tanzania	3
A2 - ???statistics.table.value.countryCode.A2???	2
Totale	52.665

Salva come PNG Salva come JPEG

Città	#
Milan	4.579
Fairfield	3.210
Ashburn	2.138
Jacksonville	1.892
Woodbridge	1.867
San Jose	1.777
Chandler	1.659
Singapore	1.448
Houston	1.371
Seattle	1.334
Wilmington	1.241
Cambridge	1.075
Dearborn	1.071
Hong Kong	977
Ann Arbor	969
Dallas	950
Izmir	724
Dublin	689
Princeton	674
Beijing	436
Nyköping	416
Dong Ket	408
The Dalles	398
Boardman	397
Chicago	368
Rome	360
Lauterbourg	319
New York	246
Como	237
San Mateo	237
San Diego	201
Ho Chi Minh City	198
Council Bluffs	196
Helsinki	160
Los Angeles	158
Hanoi	143
Santa Clara	137
Ogden	123
London	109
Guangzhou	103
Abuja	100
Orem	98
Tokyo	95
São Paulo	88
Düsseldorf	86
Hefei	83
Zhengzhou	78
Kunming	76
Shanghai	72
Washington	72
Munich	63
Kocaeli	60
Nanjing	60
Norwalk	60
Frankfurt am Main	55
Mexico City	53
Chennai	50
Redmond	50
Warsaw	46
Montreal	40
Phoenix	38
Denver	37
Toronto	37
Brooklyn	36
Brussels	36
Hangzhou	36
Stockholm	36
Jinan	33
Manchester	33
San Francisco	33
Verona	31
Atlanta	30
Shenzhen	30
Tianjin	30
Brno	28
Amsterdam	26
Haiphong	26
Nanchang	26
Vienna	26
Buffalo	25
Da Nang	25
Poplar	23
Johannesburg	22
Pune	22
Rio de Janeiro	22
Paris	21
North Bergen	20
Baghdad	19
Turku	19
Kilburn	18
Madrid	18
Mumbai	18
Nuremberg	18
Tashkent	18
Ankara	17
Changsha	17
Varese	17
Berlin	16
Boston	16
Chengdu	16
Totale	37.395

Salva come PNG Salva come JPEG

Nome	#
The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy	335
Vitreous Substitutes: The Present and the Future.	293
A teleconsultation network improves the efficacy of anti-VEGF therapy in retinal diseases.	283
Macular hole surgery: The healing process of outer retinal layers to visual acuity recovery	279
Iopanoic acid rapidly controls Type I amiodarone-induced thyrotoxicosis prior to thyroidectomy	276
Graves' ophthalmopathy	270
The phenotype of newly diagnosed Graves’ disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study	262
Process to radioactive iodine treatment for Graves' hyperthyroidism: condemned or absolved?	256
Simultaneous medullary and papillary thyroid cancer: two case reports.	255
Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management	250
Masked hypertension in newly diagnosed hypothyroidism: a pilot study	249
A 2013 European survey of clinical practice patterns in the management of Graves' disease	245
Cardiometabolic healthy and unhealthy obesity: does vitamin D play a role?	243
Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study	231
The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study	227
Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial	225
Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European Endocrinologists	224
Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of thyroid autoimmunity: a narrative review	221
Consensus Statement of the European Group on Graves' Orbitopathy (EUGOGO) on Management of Graves' Orbitopathy	220
The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy	220
Absence of serum thyroid hormone autoantibodies in patients chronically treated with amiodarone	218
Pituitary apoplexy during pregnancy: A rare, but dangerous headache	217
Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves' orbitopathy?	216
Graves' hyperthyroidism of recent onset and Graves' orbitopathy: to ablate or not to ablate the thyroid?	214
PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012	213
Oral steroid prophylaxis for Graves' orbitopathy after radioactive iodine treatment for Graves' disease is not only effective, but also safe	211
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO	210
Features and outcome of differentiated thyroid carcinoma associated with Graves' disease: results of a large, retrospective, multicenter study	210
Outcome prediction of treatment of Graves' hyperthyroidism with antithyroid drugs	208
Can a patient-tailored treatment approach for Graves' disease reduce mortality?	208
Nutrizione iodica e ipertiroidismo: quello che c’è da sapere	207
Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study	205
Thyroid hormone treatment for differentiated thyroid carcinoma: What drug, how long, what dose?	204
Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association	203
Pain perception, blood pressure levels, and peripheral benzodiazepine receptors in patients followed for differentiated thyroid carcinoma: a longitudinal study in hypothyroidism and during hormone treatment	203
Physical performance in newly diagnosed hypothyroidism: a pilot study	203
Time interval in diagnosis and treatment of papillary thyroid cancer: a descriptive, retrospective study	203
Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases	201
Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH)	199
Plasma total and acylated ghrelin concentrations in patients with clinical and subclinical thyroid dysfunction	198
Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment	198
Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal	197
The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis.	197
The clinical enigma of the “Flea catcher” by Georges de La Tour: a pregnant sinner with pre-eclampsia or a hypothyroid girl?	197
Novel treatment modalities for Graves' orbitopathy	195
Graves' orbitopathy: do not give it for granted	195
Serum TSH measurements by a sensitive enzyme immunoassay discriminate euthyroid from hyperthyroid subjects and avoid the need for TRH test during suppressive therapy with L-thyroxine	194
Adjuvant effect of lithium on radioiodine treatment of hyperthyroidism	192
An update on medical management of Graves' ophthalmopathy	192
Medullary thyroid carcinoma: surgical treatment advances	191
Lack of nocturnal serum thyrotropin surge after surgery	189
Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy?	189
Radioactive iodine thyroid uptake in patients with amiodarone iodine-induced thyroid dysfunction	188
Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy	188
Iodine supplementation in women of reproductive age: a survey of clinical practice among Italian gynecologists and midwives	188
The effect of altered thyroid function on serum fructosamine concentrations	187
More on smoking habits and Graves' ophthalmopathy	187
Characterization of nascent and secreted thyroxine-binding globulin in cultured human hepatoma (Hep G2) cells	186
Amiodarone and the thyroid	186
Interference of thyroglobulin in TSAb detection by radioreceptor assay	185
Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.	184
Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center	183
Maria Carolina of Austria, Queen of Naples and Sicily: a possible case of Graves' orbitopathy	183
Studies on the occurrence of ophthalmopathy in Graves' disease	182
Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids	182
2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction	182
Gastric Xanthomatous Hyperplastic Polyps – Just an Incidental Endoscopic Finding?	182
Free thyroxine values in dried blood spots on filter paper in newborns are related to both gestational age and birth body weight	181
Thyroid vascularity and blood flow are not dependent on serum thyroid hormone levels:studies in vivo by color flow Doppler sonography	181
Predictive score for the development or progression of Graves' orbitopathy in patients with newly diagnosed Graves' hyperthyroidism	180
Diagnosis of amiodarone iodine-induced thyrotoxicosis (AIIT) associated with severe nonthyroidal illness	179
Recommendations for treatment of hypothyroidism with levothyroxine and levotriiodothyronine: a 2016 position statement of the Italian Society of Endocrinology and the Italian Thyroid Association	179
Graves' disease and Turner's syndrome	178
Human serum thyrotrophin measurement by ultrasensitive immunoradiometric assay as a first-line test in the evaluation of thyroid function	177
Orbital radiotherapy for Graves' ophthalmopathy	177
Graves'-like orbitopathy: do not forget IgG4-related disease	176
Thyroid hormone regulation of cell migration and oxidative metabolism in polymorphonuclear leukocytes: clinical evidence in thyroidectomized subjects on thyroxine replacement therapy.	175
Shortening Hospital Stay for Thyroid Surgery.	175
Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy	175
Graves' orbitopathy: imperfect treatments for a rare disease	175
Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: a 2015 Italian Society of Endocrinology consensus statement	175
Comparison between thyroid-stimulating and TSH-binding inhibiting immunoglobulins of Graves' disease	174
Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: Results of a prospective, single-blind, randomized study	174
Effects of the antileukemic drug L-asparaginase on sex-hormone binding globulin: studies in vivo and in vitro	173
Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients	173
The age of patients with thyrotoxicosis factitia in Italy from 1973 to 1996	173
Radioimmunoassay of thyroid hormones	172
Effect of the antileukemic agent L-asparaginase on thyroxine-binding globulin and albumin synthesis in cultured human hepatoma (Hep G2) cells	172
Biosynthesis of a novel thyroxine-binding protein (27 K protein) in human hepatoma (Hep G2) cells	171
Management of Graves' ophthalmopathy: reality and perspectives	171
Thyroid hormone and thyrotropin regulate intracellular free calcium concentrations in human polymorphonuclear leukocytes: in vivo and in vitro studies	171
2018 European thyroid association guideline for the management of graves' hyperthyroidism	171
Changes in radioimmunoassayable prealbumin (TBPA) serum levels from birth to adulthood	170
Effect of amiodarone on circulating antithyroid antibodies	170
Radioiodine therapy and Graves' ophthalmopathy	170
Cigarette smoking: Number one enemy for Graves ophthalmopathy	170
Potassium perchlorate only temporarily restores euthyroidism in patients with amiodarone-induced hypothyroidism who continue amiodarone therapy	169
An update on the pharmacological management of hyperthyroidism due to Graves' disease	169
Relationship between management of hyperthyroidism and course of the ophthalmopathy	169
Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement	168
Totale	20.047

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	212.899
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	212.899

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	3.205	0	465	262	133	196	144	175	183	265	569	306	507
2022/2023	4.398	496	246	391	422	319	949	4	540	582	150	178	121
2023/2024	7.478	1.101	1.179	1.141	1.443	1.532	496	52	157	188	54	23	112
2024/2025	4.421	20	64	889	105	103	243	200	365	466	292	342	1.332
2025/2026	11.354	693	730	747	1.311	1.010	549	2.526	706	1.360	720	577	425
2026/2027	346	311	35	0	0	0	0	0	0	0	0	0	0
Totale													52.962